SAN DIEGO, June 21, 2016 /PRNewswire/ -- Pharmatek, a contract development and manufacturing organization supporting the pharmaceutical industry, today announced that it has made a substantial investment into its spray drying capabilities. The Company has purchased a second GEA Niro Mobile Minor™, in addition to a ProCepT™ 4M8-Trix™, and a GEA Niro SD Micro™ for the development and GMP manufacture of amorphous spray dried dispersions (SDD).
The purchases complement existing spray drying equipment, including a GEA Niro Mobile Minor and a Buchi B-290. Pharmatek has seen rising demand in SDD across the industry and received specific client requests to increase spray dry capacity.
"Expanding our SDD capacity is driven by significant client demand and is part of Pharmatek's continuing efforts to provide a comprehensive range of bioavailability enhancement solutions for our clients," said Tim Scott, president of Pharmatek. "We are committed to adding new technologies and increasing capacity in development areas that our clients care about."
Pharmatek offers formulation development, process scale-up and GMP manufacturing services for small molecules and peptides. Spray drying is part of the Company's comprehensive amorphous dispersion drug development capabilities that include physical characterization, preformulation testing, analytical development, formulation development and GMP manufacturing of finished dosage forms.
Spray drying is a key component of the Company's solubility enhancement toolkit and platform screening program. The Company's robust suite of technologies includes micronization, spray drying, hot-melt complexation, and liquid-filled-capsule development. Utilizing a data-driven, agnostic approach, Pharmatek screens multiple technologies to determine the best path forward for a given compound and client.
About Pharmatek
Pharmatek is a dosage form development and GMP manufacturing company providing full-service pharmaceutical chemistry product development and manufacturing for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, clinical packaging, labeling and distribution, and cytotoxic and high-potency drug development.
Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the website http://www.pharmatek.com or by calling 858-805-6383.
Company Contact:
Elizabeth Hickman, Associate Director, Marketing
Pharmatek Laboratories, Inc.
(619) 772-9555
[email protected]
Photo - http://photos.prnewswire.com/prnh/20160620/381627
Logo - http://photos.prnewswire.com/prnh/20160620/381640LOGO
SOURCE Pharmatek
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article